Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 4, 2022MedicineOpen Access

Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients

View Full Paper
Ask AI
Bookmark
Share

Key result

Sacubitril valsartan significantly reduced the heart failure readmission rate (7.14% vs 18.60%) and improved left ventricular ejection fraction compared to valsartan in diabetic patients with heart failure with midrange ejection fraction after acute myocardial infarction.

Why the study?

The clinical efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients needed evaluation.

Does sacubitril valsartan improve left ventricular function and reduce heart failure readmissions compared to valsartan in diabetic patients with heart failure with midrange ejection fraction after acute myocardial infarction?

Population

Diabetic patients with HF and midrange ejection fraction after AMI (84 sacubitril valsartan, 86 valsartan)

Comparison

Sacubitril valsartan vs valsartan

Design

Retrospective study

Follow-up

12 months

Discussion

Loading...

Member takes

Overview

May support sacubitril valsartan in diabetic HFmrEF post-MI; hypothesis-generating and requires randomized confirmation.

Study Design

Type

Cohort (n=170)

Multicenter

No

Structured PICO

Does sacubitril valsartan improve left ventricular function and reduce heart failure readmissions compared to valsartan in diabetic patients with heart failure with midrange ejection fraction after acute myocardial infarction?

P
Population
170 diabetic patients with heart failure with midrange ejection fraction after acute myocardial infarction, followed for 12 months.
E
Exposure
Sacubitril valsartan (initial dose 25 mg twice daily, gradually increased to target dose according to blood pressure) added to routine treatment
C
Comparator
Valsartan 80 mg once daily added to routine treatment
O
Outcome
Left ventricular end diastolic dimension, left ventricular ejection fraction, and readmission rate due to heart failure at 12 months

Main Result

Absolute Event Rate: 7.14% vs 18.6%

p-value: p=0.038

In diabetic patients with HFmrEF following an acute myocardial infarction, sacubitril valsartan improves left ventricular function and reduces heart failure readmissions more effectively than valsartan.

Limitations

  • Small sample size
  • Short follow-up period
  • Retrospective observational design

Cite This Study

A 2022 study conducted a cohort in Heart failure with midrange ejection fraction (HFmrEF) after acute myocardial infarction in diabetic patients (n=170). Sacubitril valsartan vs. Valsartan (80 mg qd) was evaluated on Readmission rate due to heart failure at 12 months (p=0.038). Sacubitril valsartan significantly reduced the heart failure readmission rate (7.14% vs 18.60%) and improved left ventricular ejection fraction compared to valsartan in diabetic patients with heart failure with midrange ejection fraction after acute myocardial infarction.

synapsesocial.com/papers/6a82fb758847014bd698f8f8https://doi.org/10.1097/md.0000000000028729
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure2019 · 63 citations
  2. 2Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation2018 · 2 citations
  3. 3LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model2019 · 39 citations
  4. 4Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta‐Analysis2015 · 35 citations
  5. 5Impact of Diabetes on Long-Term Survival After Acute Myocardial Infarction2001 · 249 citations